Antares Pharma, Inc. (ATRS)

[H2R]

Oct. 20 PDUFA, 2 1/2 months away

And the execution so far is going well...

http://www.antarespharma.com/application/files/5015/0214/0282/ATRS_Q217_Final.pdf

Second Quarter 2017 and Recent Highlights

Reported second quarter 2017 revenue of $13.4 million, loss per share of $0.02 and cash, cash equivalents and short-term investments of $43.4 million at June 30, 2017.

Completed a non-dilutive debt financing with Hercules Capital (HTGC). The five-year debt agreement provides Antares the ability to draw up to $35.0 million, with the first tranche of $25.0 million funded upon execution of the agreement.

OTREXUP® total prescriptions grew 16% sequentially versus the first quarter of 2017 and increased 14% versus the second quarter of 2016 according to data from Symphony Health Solutions.

Sumatriptan Injection USP total prescriptions increased to a 26% share of the migraine auto injector market in the second quarter of 2017, up from 21% in the first quarter of 2017 according to data from Symphony Health Solutions.

Announced that data from the 52 week phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate delivered through the QuickShot® auto injector was presented at a moderated poster session at the annual American Urological Association meeting.